Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Protein Kise C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Overview
Protein Kise C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Protein Kise C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Protein Kise C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Companies Involved in Therapeutics Development
Astellas Pharma Inc
Bristol-Myers Squibb Co
EpiAxis Therapeutics Pty Ltd
HotSpot Therapeutics Inc
Protein Kise C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Drug Profiles
AS-2521780 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-90005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
englerin A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EPI-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Ewing Sarcoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PRKCQ for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein Kise C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Dormant Products
Protein Kise C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Discontinued Products
Protein Kise C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Product Development Milestones
Featured News & Press Releases
Oct 01, 2017: EpiAxis Therapeutics recruits first Phase 1 patient
Feb 11, 2016: UC launches new cancer therapeutic company
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020


List of Tables


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Astellas Pharma Inc, H2 2020
Pipeline by Bristol-Myers Squibb Co, H2 2020
Pipeline by EpiAxis Therapeutics Pty Ltd, H2 2020
Pipeline by HotSpot Therapeutics Inc, H2 2020
Dormant Projects, H2 2020
Discontinued Products, H2 2020